This is particularly important to recognize in the AYA population, where gliomas with alterations in the MAPK pathway or MYB and MYBL1 have distinctly different prognoses from other glioma subtypes and offer possibilities for targeted therapy (5). Here, MYBL1 is linked to glioma.